Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the pharmacokinetics PK and safety of ublituximab given as a subcutaneous SC injection in people with relapsing multiple sclerosis MS. The study evaluates how the drug behaves in the body when injected at different sites and compares the bioavailability when administered by a prefilled pen versus a syringe. This Phase 2 trial is focused on treatment and aims to understand the best method of delivering ublituximab subcutaneously. Participants will receive ublituximab SC either at one of three different injection sites using a syringe or via a prefilled pen. The study randomly assigns participants to receive the drug using either the prefilled pen or the syringe. The treatment period includes assessments up to 12 weeks for primary PK measures and up to 120 weeks for safety and plasma concentration monitoring. During the study, participants will have blood samples taken to measure drug levels and safety will be monitored by tracking any adverse events. They will also report their satisfaction with the injection method through questionnaires up to week 96. The main outcome measured is the area under the curve AUC of ublituximab at steady state by week 12, with longer follow-up to assess plasma concentrations and side effects. The total study duration extends up to nearly three years, ensuring extended safety and treatment evaluation.